CADTH Canadian Drug Expert Committee recommendation: Tapentadol hydrochloride (Nucynta extended-release -- Paladin Labs Inc.) indication : management of pain severe enough to require daily, continuous, long-term opioid treatment, and that is opioid responsive; and for which alternative treatment options are inadequate
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Physical Description: | 1 PDF file (9 pages) |
|---|